A Phase I Study of the Safety, Tolerability, Pharmacokinetics Profiles and Preliminary Efficacy of 3D185 Monotherapy in Subjects With Advanced Solid Tumors
Latest Information Update: 03 Jun 2025
At a glance
- Drugs HH 185 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors 3D Medicines
Most Recent Events
- 29 May 2025 Planned End Date changed from 30 Dec 2024 to 30 Dec 2026.
- 29 May 2025 Planned primary completion date changed from 30 Dec 2024 to 30 Dec 2025.
- 23 Aug 2024 Planned End Date changed from 30 Jun 2024 to 30 Dec 2024.